Edgewise Therapeutics, Inc.
NASDAQ:EWTXBiotechnology
+$1.11 today
- Market cap
- $4.45B
- Beta
- 0.30
- P/E (TTM)
- -21.9
- EPS (TTM)
- -$1.64
Volume 0.87M
Average 1.32M
EWTX Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Edgewise Therapeutics, Inc.NASDAQ: EWTX
Other Income / Expenses · Q3 FY2026 · quarter ended Sep 2026
Other income / expenses growth accelerates
Q3 FY2026 other income / expenses of $1.37B rose 21987.0% year over year, ahead of the +5729.5% change in trailing-twelve-month other income / expenses. Sequentially, it rose 29528.0% from the prior quarter. Over 3 fiscal years it compounded at +80.5% a year.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +21987.0% holds above the trailing-twelve-month pace of +5729.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 23.61M USD
- Year-over-year change
- -5.6%
- 4-year CAGR
- +176.8%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.61M | -5.6% |
| FY2024 | 2024-12-31 | 25.02M | +76.3% |
| FY2023 | 2023-12-31 | 14.19M | +253.3% |
| FY2022 | 2022-12-31 | 4.02M | +899.5% |
| FY2021 | 2021-12-31 | 402K | — |
Other Income / Expenses vs competitors
How EWTX compares with its peers on the latest reported figures
- EWTX's LTM Sep 2026 other income / expenses of $1.38B is the highest of the 10 companies compared; the peer median is $6.42M.
- Its year-over-year change of +5729.5% is the highest of 10, against a peer median of -32.7%.
- Over three fiscal years its annual growth of +80.5% compares with a peer median of +66.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.38B | +5729.5% | +80.5% | — | |
| LTM Mar 2026 | $65.43M | +239.3% | — | 3.0% | |
| LTM Jun 2026 | $17.55M | -37.4% | +97.2% | — | |
| LTM Mar 2026 | $14.2M | +6.7% | +60.9% | 44.3% | |
| LTM Mar 2026 | $13.26M | -32.7% | +71.0% | 231.0% | |
| LTM Mar 2026 | $6.42M | -36.5% | +80.0% | — | |
| LTM Mar 2026 | $5.34M | +140.8% | +66.0% | — | |
| LTM Mar 2026 | $4.68M | +44.4% | -38.0% | — | |
| LTM Mar 2026 | $4.08M | -37.0% | +11.3% | — | |
| LTM Jun 2026 | -$183.33M | -250.6% | — | 18.2% | |
| Peer median (excluding EWTX) | $6.42M | -32.7% | +66.0% | 31.2% | |
Competitors are the stored peer set for EWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.27M |
| Gross Profit | 0 | 0 | 0 | 0 | (2.27M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.19M | 54.03M | 90.91M | 126.97M | 151.39M |
| Selling, General & Admin | 11.03M | 17.63M | 23.45M | 31.87M | 40.02M |
| Operating Expenses | 43.22M | 71.66M | 114.36M | 158.83M | 189.14M |
| Depreciation & Amortization | 272K | 538K | 1.73M | 2.29M | 2.27M |
| EBITDA | (42.54M) | (63.08M) | (98.43M) | (131.52M) | (165.53M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (43.22M) | (71.66M) | (114.36M) | (158.83M) | (191.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 402K | 2.66M | 14.19M | 25.02M | 23.61M |
| Interest Expense | 0 | 4.02M | 0 | 0 | 0 |
| Other Income / Expenses | 402K | 4.02M | 14.19M | 25.02M | 23.61M |
| Income Before Tax | (42.81M) | (67.64M) | (100.16M) | (133.81M) | (167.8M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (42.81M) | (67.64M) | (100.16M) | (133.81M) | (167.8M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.86) | (1.26) | (1.57) | (1.45) | (1.63) |
| EPS (Diluted) | (0.86) | (1.26) | (1.57) | (1.45) | (1.63) |
| Weighted Avg Shares | 49.5M | 53.59M | 63.72M | 92.41M | 102.93M |
| Weighted Avg Shares (Diluted) | 49.5M | 53.59M | 63.72M | 92.41M | 102.93M |
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
Intrinsic Alpha fair value
Locked
Current Price
$41.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.